Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Heidelberg Pharma AGWBO:HPHA 10 Market Cap is €119.30 Mil as of Jul. 16, 2026. GuruFocus rates WBO:HPHA with a GF Score™ of 10/100 and a GF Value™ of €0.94 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,423 Biotechnology companies, Heidelberg Pharma AG ranks better than 52.14% on this metric.
Heidelberg Pharma AG's quarterly market cap
stayed the same
from Nov. 2025 (€0.00 Mil) to Feb. 2026 (€0.00 Mil) but then
increased
from Feb. 2026 (€0.00 Mil) to May. 2026 (€126.78 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Heidelberg Pharma AG's Enterprise Value for Today is €94.42 Mil.
Heidelberg Pharma AG (WBO:HPHA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Heidelberg Pharma AG Market Cap Related Terms
Heidelberg Pharma AG Market Cap Historical Data
* Premium members only.
The historical data trend for Heidelberg Pharma AG's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:HPHA vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Heidelberg Pharma AG's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Heidelberg Pharma AG Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's Market Cap distribution charts can be found below:
* The bar in red indicates where Heidelberg Pharma AG's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Heidelberg Pharma AG's Market Cap for the fiscal year that ended in Nov. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Heidelberg Pharma AG (WBO:HPHA) has a Market Cap of €119.30 Mil as of Jul. 16, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Heidelberg Pharma AG and its competitors. According to the industry distribution chart, Heidelberg Pharma AG ranks #681 out of 1423 companies in the Biotechnology industry, placing it in the top 47.9%.
Is Heidelberg Pharma AG's Market Cap too high?
Heidelberg Pharma AG's current Market Cap is €119.30 Mil. Based on the distribution chart, Heidelberg Pharma AG ranks #681 out of 1423 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Heidelberg Pharma AG has a GF Score™ of 10/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Heidelberg Pharma AG's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Heidelberg Pharma AG ranks #681 out of 1423 companies for Market Cap. This puts Heidelberg Pharma AG in the upper half of its industry. The industry median Market Cap is 114.24. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 114.24, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Heidelberg Pharma AG and its competitors. For the Biotechnology industry, the median Market Cap is 114.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Heidelberg Pharma AG's current Market Cap is €119.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Heidelberg Pharma AG stock overvalued right now?
Based on GuruFocus' analysis, Heidelberg Pharma AG (WBO:HPHA) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.94, compared to a current price of €2.55 — trading 171.3% above its estimated fair value. The current Market Cap is €119.30 Mil. Heidelberg Pharma AG's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Heidelberg Pharma AG (WBO:HPHA), the current Market Cap is €119.30 Mil as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Heidelberg Pharma AG (WBO:HPHA) Overvalued in 2026?
Based on GuruFocus' analysis, Heidelberg Pharma AG stock appears to be overvalued.
The current stock price of €2.55 is trading 171.3% above its estimated GF Value™ of €0.94.
GuruFocus considers Heidelberg Pharma AG to be Significantly Overvalued.
Key valuation signals for WBO:HPHA:
Market Cap: €119.30 Mil
GF Value™: €0.94 vs. price of €2.55 (171.3% above fair value)
No single metric tells the full story. See the WBO:HPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Heidelberg Pharma AG is a biopharmaceutical company developing oncology treatments through antibody drug conjugates (ADCs), which combine antibody specificity with toxin potency to selectively target and kill cancer cells. The Company researches, develops, and produces these ADCs, and has built an ADC toolbox using various antibodies and payloads to address multiple cancers and overcome tumor resistance. Its activities focus on its proprietary ATAC technology based on Amanitin, the toxin of the death cap mushroom, leveraging its biological mechanism as a novel cancer therapy. The ATAC platform is used to develop proprietary ADC candidates and is also applied in collaborations with third parties.
10GF Score
Get the complete analysis for WBO:HPHA
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:HPHA has been successfully added to your 
